企業概要
CRISPR Therapeutics AG is a gene editing enterprise dedicated to the development of gene-based pharmaceuticals intended for the treatment of serious human diseases. The company leverages its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform to facilitate precise gene editing technologies. Operating within the healthcare sector and specifically the biotechnology industry, the firm functions as an innovator in advanced therapeutic modalities. With a market capitalization of $4.96B and annual revenue of $3.51M, the company's scale reflects a significant valuation relative to its current financial output, indicative of a firm heavily invested in research and development rather than mature commercial operations. The employee count is not disclosed in available records, suggesting a lean operational structure typical of early-stage biotechnology entities where capital is prioritized for scientific progress over workforce expansion.
財務健全性
The company reported a revenue of $3.51M over the trailing twelve months (TTM), yet recorded a net income of $-581,598,976 and an EBITDA of $-548,838,976. The substantial gap between the modest revenue figure and the massive net loss reveals a cost structure dominated by high research and development expenditures and operational expenses common in clinical-stage biotechnology. Free cash flow stands at $-205,623,744, indicating that the company is burning cash to fund its operations and scientific trials, which limits immediate financial flexibility but is typical for firms in the discovery phase. Despite these losses, the company holds cash reserves of $1.98B, providing a substantial buffer against debt obligations of $206.75M. The balance sheet appears conservative in terms of absolute liquidity given the $1.98B cash position significantly outweighs the $206.75M debt, though the leverage is measured by a debt-to-equity ratio of 10.76. Short-term liquidity is robust, evidenced by a current ratio of 13.32, which suggests the company possesses ample current assets to cover its short-term liabilities many times over. However, the return on equity is negative at -30.2% and the return on assets is -15.8%, metrics that indicate the management team has not yet generated positive returns on the capital deployed, a status expected for companies still navigating clinical trials.
バリュエーション評価
The trailing twelve-month P/E ratio is not applicable (N/A) due to the lack of positive earnings, while the forward P/E stands at -12.35. The discrepancy between these metrics, coupled with the negative valuation multiples, implies that the market is pricing the stock based on future potential rather than current profitability, reflecting an expected earnings trajectory that has not yet materialized. The price-to-book ratio is 2.58, suggesting the market values the company at a premium of roughly 158% over its tangible book value, which often reflects the high value of intangible assets like intellectual property and patent portfolios. Alternative valuation metrics such as the price-to-sales ratio of 1414.35 and the EV/EBITDA of -5.82 further highlight that traditional profitability-based valuation models are inapplicable, pointing instead to a valuation driven by pipeline potential and market exclusivity. The stock has traded between a 52-week low of $30.52 and a 52-week high of $78.48, meaning the current price sits at a variable point within this range dependent on real-time market conditions. The beta value is 1.79, indicating that the stock price is significantly more volatile than the broader market, rising and falling more sharply during periods of market turbulence.
Growth & Income
The revenue growth year-over-year is -97.6%, while earnings growth is not applicable (N/A) due to the company's unprofitable status. The absence of positive earnings growth relative to revenue is a function of the company's current operational stage, where revenues are minimal compared to the massive upfront costs of drug development. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute profits to shareholders but instead retains all available capital to fund research and development activities. This reinvestment strategy is standard for biotechnology firms that prioritize long-term pipeline advancement over immediate income distribution to investors. Consequently, the overall growth and income profile is characterized by negative current revenue growth, zero dividend payouts, and a reliance on external capital markets or existing cash reserves to sustain operations until commercial milestones are achieved.